GALECTIN THERAPEUTICS INC — Director's Dealing 2019

Jan 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2019-01-16

Reporting Person: LEWIS JOEL (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-16	Common Stock	A	11653	$4.72	Acquired	63133	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-16	Stock option (right to buy)	$4.72	A	35000	Acquired	2029-01-16	Common stock (35000)	Direct

Footnotes

F1: These restricted shares were issued in lieu of cash retainer and meeting fees of $55,000 for 2019. Restrictions on the shares lapse at a rate of 25% at the end of each calendar quarter in 2019.

F2: The options vest 100% on January 16, 2020.